Clinical influences of anticentromere antibody on primary Sjögren’s syndrome in a prospective Korean cohort = Clinical influences of anticentromere antibody on primary Sjögren’s syndrome in a prospective Korean cohort

다국어 초록 (Multilingual Abstract)

Background/Aims: This study was performed to clarify influences of anticentromere antibody (ACA) on clinical phenotypes of primary Sjögren’s syndrome (pSS) patients in Korea.
Methods: We assessed 318 patients who met the 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for pSS. All patients were selected from the Korean Initiative of primary Sjögren’s Syndrome (KISS), a prospective cohort. Among them, 53 patients were positive for ACA, while another 265 patients were not. We compared various clinical data including demographic features, extra-glandular manifestations (EGMs), clinical indices, and laboratory values available from the KISS database between the two groups.
Results: Patients in the ACA-positive pSS group were older (p = 0.042), and had higher xerostomia inventory scores (p = 0.040), whereas glandular dysfunction represented with Schirmer I test was more severe in the ACA-negative group. More frequent Raynaud’s phenomenon and liver involvement (both p < 0.001) and less articular involvement (p = 0.037) were observed among the EGMs in the ACA-positive group. Less frequency of leukopenia (p = 0.021), rheumatoid factor (p < 0.001), anti-Ro/SSA antibody positivity (p < 0.001), and hypergammaglobulinemia (p = 0.006), as well as higher positivity rates of anti-nuclear antibody and anti-topoisomerase antibody (p < 0.001 and p = 0.006, respectively) were found in the laboratory data in the ACA-positive pSS group.
Conclusions: Considering distinct phenotypes in hematological and serological features and EGMs, we should monitor the occurrence of these clinical features among pSS patients with ACA in caution.

참고문헌 (Reference)

1 Thomson WM, "The Xerostomia Inventory : a multi-item approach to measuring dry mouth" 16 : 12-17, 1999

2 Bournia VK, "Subgroups of Sjogren syndrome patients according to serological profiles" 39 : 15-26, 2012

3 Lee YK, "South Korean time trade-off values for EQ-5D health states : modeling with observed values for 101 health states" 12 : 1187-1193, 2009

4 Caramaschi P, "Sjogren’s syndrome with anticentromere antibodies" 64 : 785-788, 1997

5 Tsianos EV, "Sjogren’s syndrome in patients with primary biliary cirrhosis" 11 : 730-734, 1990

6 Fox RI, "Sjogren’s syndrome" 366 : 321-331, 2005

7 Vitali C, "Sjogren’s Syndrome Disease Damage Index and Disease Activity Index : scorlittleing systems for the assessment of disease damage and disease activity in Sjogren’s syndrome, derived from an analysis of a cohort of Italian patients" 56 : 2223-2231, 2007

8 Brito-Zeron P, "Sjogren syndrome" 2 : 16047-, 2016

9 Schiffman RM, "Reliability and validity of the Ocular Surface Disease Index" 118 : 615-621, 2000

10 Malladi AS, "Primary Sjogren’s syndrome as a systemic disease : a study of participants enrolled in an international Sjogren’s syndrome registry" 64 : 911-918, 2012

11 Suzuki Y, "Impact of double positive for anti-centromere and anti-SS-a/Ro antibodies on clinicopathological characteristics of primary Sjogren’s syndrome : a retrospective cohort study" 28 : 872-878, 2018

12 Seror R, "EULAR Sjogren’s syndrome disease activity index(ESSDAI) : a user guide" 1 : e000022-, 2015

13 Seror R, "EULAR Sjogren’s Syndrome Patient Reported Index(ESSPRI) : development of a consensus patient index for primary Sjogren’s syndrome" 70 : 968-972, 2011

14 Yang WH, "Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?" 2 : 1116-1122, 2004

15 Gelber AC, "Distinct recognition of antibodies to centromere proteins in primary Sjogren’s syndrome compared with limited scleroderma" 65 : 1028-1032, 2006

16 Park Y, "Distinct clinical characteristics of anti-Ro/SSA-negative primary Sjogren’s syndrome : data from a nationwide cohort for Sjogren’s syndrome in Korea" 37 (37): 107-113, 2019

17 van Bijsterveld OP, "Diagnostic tests in the Sicca syndrome" 82 : 10-14, 1969

18 Peene I, "Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB : the range of associated diseases differs according to the detailed serotype" 61 : 1090-1094, 2002

19 Katano K, "Clinical and laboratory features of anticentromere antibody positive primary Sjogren’s syndrome" 28 : 2238-2244, 2001

20 Tsukamoto M, "Clinical and immunological features of anti-centromere antibody-positive primary Sjogren’s syndrome" 5 : 499-505, 2018

21 Vitali C, "Classification criteria for Sjogren’s syndrome : a revised version of the European criteria proposed by the American-European Consensus Group" 61 : 554-558, 2002

22 Ramos-Casals M, "Atypical autoantibodies in patients with primary Sjogren syndrome : clinical characteristics and follow-up of 82 cases" 35 : 312-321, 2006

23 Daniels TE, "Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjogren’s syndrome among 1, 726registry participants" 63 : 2021-2030, 2011

24 Baer AN, "Association of anticentromere antibodies with more severe exocrine glandular dysfunction in Sjogren’s syndrome:analysis of the Sjogren’s International Collaborative Clinical Alliance Cohort" 68 : 1554-1559, 2016

25 Takeshita M, "Antigen-driven selection of antibodies against SSA, SSB and the centromere ‘complex’, including a novel antigen, MIS12complex, in human salivary glands" 79 : 150-158, 2020

26 Tanaka N, "Anticentromere antibody-positive primary Sjogren’s syndrome : epitope analysis of a subset of anticentromere antibody-positive patients" 27 : 115-121, 2017

27 Bournia VK, "Anticentromere antibody positive Sjogren’s syndrome : a retrospective descriptive analysis" 12 : R47-, 2010

28 Nakamura H, "Anti-centromere antibody-seropositive Sjogren’s syndrome differs from conventional subgroup in clinical and pathological study" 11 : 140-, 2010

29 Lee KE, "Anti-centromere antibody-positive Sjogren’s syndrome: a distinct clinical subgroup?" 18 : 776-782, 2015

30 Shiboski SC, "American College of Rheumatology classification criteria for Sjogren’s syndrome: a data-driven, expert consensus approach in the Sjogren’s International Collaborative Clinical Alliance cohort" 64 : 475-487, 2012

31 Montano-Loza AJ, "Abnormal hepatic biochemistries and clinical liver disease in patients with primary Sjogren’s syndrome" 6 : 150-155, 2007

32 Whitcher JP, "A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjogren’s Syndrome International Registry" 149 : 405-415, 2010

33 Notarstefano C, "A clinical and histopathological analysis of the anti-centromere antibody positive subset of primary Sjogren’s syndrome" 36 (36): 145-149, 2018

34 Shiboski CH, "2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren’s syndrome : a consensus and data-driven methodology involving three international patient cohorts" 69 : 35-45, 2017